{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"IRR will be assessed during the first infusion using the accelerated dosing regimen. Number of patients who develop grade 3 or above IRR utilizing the accelerated infusion will be used for safety analysis.","groups":[{"description":"Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Daratumumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Infusion-related Reactions (IRR)","type":"SECONDARY","unitOfMeasure":"participants with IRR"}